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Hyperbaric oxygen brain injury treatment
(HOBIT) trial: a multifactor design with
response adaptive randomization and
longitudinal modeling
Byron J. Gajewski,a* Scott M. Berry,a,b William G. Barsan,c
Robert Silbergleit,c William J. Meurer,c,d Renee Martin,e and
Gaylan L. Rockswoldf,g
The goals of phase II clinical trials are to gain important information about the performance of novel treatments and decide
whether to conduct a larger phase III trial. This can be complicated in cases when the phase II trial objective is to identify a
novel treatment having several factors. Such multifactor treatment scenarios can be explored using fixed sample size trials.
However, the alternative design could be response adaptive randomization with interim analyses and additionally, longitudi-
nal modeling whereby more data could be used in the estimation process. This combined approach allows a quicker and more
responsive adaptation to early estimates of later endpoints. Such alternative clinical trial designs are potentially more pow-
erful, faster, and smaller than fixed randomized designs. Such designs are particularly challenging, however, because phase
II trials tend to be smaller than subsequent confirmatory phase III trials. The phase II trial may need to explore a large num-
ber of treatment variations to ensure that the efficacy of optimal clinical conditions is not overlooked. Adaptive trial designs
need to be carefully evaluated to understand how they will perform and to take full advantage of their potential benefits. This
manuscript discusses a Bayesian response adaptive randomization design with a longitudinal model that uses a multifactor
approach for predicting phase III study success via the phase II data. The approach is based on an actual clinical trial design for
the hyperbaric oxygen brain injury treatment trial. Specific details of the thought process and the models informing the trial
design are provided. Copyright © 2016 John Wiley & Sons, Ltd.
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1. INTRODUCTION
This manuscript describes a phase II clinical trial adaptive design
for selecting the combination of hyperbaric oxygen (HBO2) treat-
ment dose parameters [pressure, frequency, and intervening nor-
mobaric hyperoxia (NBH)] that provide the greatest improvement
in the rate of good neurological outcome versus standard care for
subjects with severe traumatic brain injury (TBI). A second goal of
this phase II trial is to determine if there is any factor combination
of HBO2 treatment that has at least a 50% probability of demon-
strating improvement in the rate of good neurological outcome
versus a control (i.e., standard care) in a subsequent phase III
confirmatory trial, assuming to be 500 in the control and 500 in
the novel arm.
Despite numerous clinical trials for treatment of TBI, subjects
with TBI have high mortality and poor outcomes [1]. Preclini-
cal and clinical investigations indicate that HBO2 is physiologi-
cally active in reducing brain injury and improving outcomes in
severe TBI [2]. There are peer-reviewed published animal stud-
ies from well-established research laboratories that indicate that
HBO2 potentially improves outcome from TBI by multiple mech-
anisms [3]. By markedly increasing oxygen (O2) delivery to the
traumatized brain, HBO2 can improve cellular energy metabolism,
attenuate cell signaling and cytosolic ischemic cascades, and
reduce subsequent necrotic and programmed cell death. Many
clinical investigations in HBO2 have steadily corroborated that
HBO2 in comparison with standard care significantly improves
markers of oxidative metabolism in relatively uninjured brain
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as well as pericontusional tissue, reduces intracranial hyperten-
sion, demonstrates improvements in markers of cerebral toxicity,
and improves clinical outcome. However, important information,
optimizing the HBO2 treatment factor combination in terms of
pressure, frequency, and whether NBH delivered following the
HBO2 treatment, is required prior to a definitive clinical efficacy
study. Preclinical investigations working with TBI models have
used pressures varying from 1.5 to 3.0 atmospheres absolute
(ATA). Clinical investigators have used pressures varying from 1.5
to 2.5 ATA. However, the lungs in severe TBI subjects have fre-
quently been compromised by direct lung injury and/or acquired
ventilator pneumonia and are susceptible to O2 toxicity. Work-
ing within these constraints, it is essential to determine the most
effective HBO2 dose schedule without producing O2 toxicity and
clinical complications. This proposed clinical trial is designed to
answer these questions and to provide important information for
a confirmatory efficacy phase III trial.
The primary endpoint is the severity adjusted Glasgow Out-
come Scale - Extended (GOS-E, binary response) at 6 months after
the patient has enrolled in this study. Moreover, GOS-E at 30 days
could be used for predicting 6-month GOS-E, allowing for accel-
erated learning of the primary endpoint through the longitudinal
modeling. The combination of the three HBO2 treatment factors
with different levels – pressure (1.5, 2.0, and 2.5 ATA), dose fre-
quency [once a day (QD) and twice daily (BID)], and NBH (with
and without) – will be studied. Not all possible combinations are
used because of potential O2 toxicity, and the trial will explore the
efficacy of nine different active arms in comparison with the con-
trol arm. If there is at least one experimental arm with sufficient
probability of being better than control at phase II, the combi-
nation of that active arm will be selected for the future phase III
trial to confirm the HBO2 efficacy. Another design constraint is the
sample size of about 200 enrolled subjects from approximately
15 clinical centers. The sample size is relatively small because of
budget constraints.
Given these constraints, this multifactor treatment design is
challenging: there are three dimensions to study, the sample size
is small, and the tool that provides the endpoint (GOS-E) is subject
to variability from the heterogeneity of the disease. In addition,
the added variability from posterior predictive distributions used
for forecasting phase III success contributes noise.
Therefore, it would be quite attractive to garner model efficien-
cies to improve later prediction. This manuscript, using a detailed
phase II clinical trial design as example, which has been tailored
for the case of multiple factors for predicting phase III success
using the phase II data, illustrates a Bayesian adaptive Q2 design
is useful. Bayesian predictive probabilities are useful to drive learn-
ing, which in itself is not necessarily novel for a phase II trial,
but has been underutilized. A potential model’s efficiency can be
improved with a main effects factor model based on the strong
assumption that there are no interactions. We also use the main
effects model in this design for getting information from the other
arms. This could have other applications, as studying related treat-
ments is common and could be done more efficiently if such
treatments are not assumed to be independent. Every subject
will still help in learning about all three factors and predicting
phase III success. However, it is believed that there is a possibil-
ity of interactions within the treatment factors, so it is decided to
use a pairwise independent model for the primary analysis. This
can be considered a hybrid design of both a pairwise indepen-
dent and main effects models. The approach based on an actual
emergency medicine clinical trial design is called the hyperbaric
oxygen brain injury treatment (HOBIT) trial.
1. Design Choice
Possible choices for the design are fixed sample size trials
or response adaptive randomization (RAR) with interim analyses
for possible success and/or futility. Other options include RAR
with longitudinal (RARCL) modeling because it can increase effi-
ciency of the trial, particularly when the short-term endpoint is
relatively predictive of the long-term endpoint and some rela-
tionship (linear, quadratic, etc.) between the two is approximately
correct [4–7].
Response adaptive randomization may provide clinical trial
designs that are more powerful, faster, and smaller than fixed
randomized designs. However, phase II trials tend to have a
smaller sample size than their subsequent confirmatory phase
III trials and may require exploration of numerous treatment
options to identify the combination of treatment parameters
most likely to improve clinical outcome. Therefore, trial designs
need to be carefully studied in order to take full advantage of
the RAR approach [8,9]. For example, a multifactor treatment
clinical trial quickly reduces to a sparse amount of human sub-
jects per treatment combination. In other words, efficiency is
achieved by considering the information of adjacent dose cells
as informative rather than independent. The RAR in dose find-
ing strategy provides a useful approach for optimal clinical trial
design in the case of a single factor with multiple doses [10]; there
is also literature on the two-factor clinical trial design [11–14];
however, there is little literature on trial design and sample
size computations using multifactor (e.g., three-factor) designs
having RAR.
The trial will utilize RAR to favor the better performing exper-
imental arms and possibly early stopping for success or futil-
ity. RAR implies using a predefined algorithm for changing the
treatment allocation during the trial based on efficacy data,
while leaving the clinical investigators blinded. In some situ-
ations, RAR allows for substantially smaller sample sizes and
provides better conclusions by favoring arms that are perform-
ing better and slowing enrollment to the arms that are per-
forming relatively poorly [15]. Although unlikely in the phase
II multi-treatment space, early termination of the study can
allow more rapid development of a promising treatment or,
more commonly, efficient identification and rejection of less
or not effective treatments that are unlikely to be beneficial if
pursued further.
2. METHODS
This section presents the details for the phase II HOBIT trial. The
goal of this phase II trial is to identify the best HBO2 treatment for
subjects with severe TBI, which would optimally combine three
HOBIT treatment factors with different levels: pressure (1.5, 2.0,
and 2.5 ATA), dose frequency (BID and QD), and NBH (with and
without). Furthermore, this manuscript also tries to predict the
phase III success based on the phase II data.
2.1. Treatment arms
There are 10 treatment arms in the trial:
We label the control arm as a D 1, and the experimental arms
as a D 2, 3, 4, 5, 6, 7, 8, 9, and 10, respectively.
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Arm .a/ Pressure (ATA) Frequency NBH
1 0 0 Without
2 2.0 QD Without
3 2.5 QD Without
4 1.5 QD With
5 2.0 QD With
6 2.5 QD With
7 1.5 BID Without
8 2.0 BID Without
9 2.5 BID Without
10 1.5 BID With
ATA, atmospheres absolute; NBH, normobaric hyperoxia; QD,
once a day; BID, twice daily.
2.2. Primary endpoint
The primary endpoint is the GOS-E assessed at 6 months after
the subject is enrolled in the clinical trial. The GOS-E is a binary
response variable with the value of success or failure. We label
it as Y6. Additionally, the GOS-E is available 1 month after enroll-
ment that will be used to inform a longitudinal model to predict
the 6-month outcome response. Similarly, we label it as Y1.
2.3. Primary analyses
In the first analysis, we define the maximally effective treat-
ment (amax/ as the treatment with the greatest effect. For
each experimental arm, we calculate the posterior probabil-
ity of being superior to control, Pr(a-1>0), where a is the
6-month GOS-E response rate for experimental arm a and
1 is that for control arm. As clinical data are analyzed by the
pairwise independent model, the phase II trial will be stopped if
one of the three following cases occurs:
(1) Early success: At each interim analysis, the trial may stop
accrual for expected success if Pr(a1>0)>0.975 for amax.
There must be at least 150 total subjects enrolled before
the trial may stop for success. If a success stopping rule is
met, then a final analysis will be conducted after all cur-
rently enrolled subjects have been followed to their final
endpoint.
(2) Early futility: At each interim analysis, the trial may stop
accrual for early futility if Pr(a-1>0)<0.55 for amax ; there-
fore, all arms would meet this inequality for futility.
(3) Final success: At the final analysis, the trial will be consid-
ered a success if Pr(a-1>0)>0.94 for any a; this inequality
would need to occur only for one arm. Otherwise, the phase
II trial will fail.
We now explain the second analysis that is using this phase II data
for the prediction of phase III success. A prediction of phase III
success is if the maximally effective treatment has a greater than
50% probability of HBO2 treatment demonstrating improvement
versus control in a subsequent confirmatory trial with size 500 in
the control and 500 in the novel treatment. A prediction of phase
III success is only calculated if Pr(a-1>0)>0.94 for the arm amax.
Note that this calculation is made using the main effects model
rather than the independent model previously mentioned. This
should increase efficiency in this prediction.
2.4. Analysis population
The intent-to-treat population will be used to analyze the data.
The intent-to-treat population will include all randomized sub-
jects, and they will be assigned to different arms based on the
randomization information regardless of the treatment received.
2.5. Adaptive design
The purpose of this phase II adaptive clinical trial design is to
explore the efficacy of different active arms in comparison with
the control arm. The trial will not compare the active arms with
each other. The trial will utilize RAR to favor the better performing
experimental arms. If the efficacy within at least one experimental
arm is promising enough, it will advance to a phase III trial and be
compared for superiority with the control arm (Figure 1). The trial
will use both a pairwise independent and main effects multiple
factor models to analyze the data based on the study objective
(more detailed information will be described in Section 2.7).
2.6. Randomization introduction
(1) Burn-in phase: An initial burn-in period of 50 subjects is
used in which these subjects are enrolled in a fixed random-
ization to each arm. A ratio of 1:1:1:1:1:1:1:1:1:1 will be used
for the burn-in period.
(2) Adaptive randomization phase: After the initial burn-in
period, adaptive randomization will be utilized. A vector of
probabilities, q D .q2, q3, q4, q5,q6, q7, q8, q9,q10/, is created
for randomizing to the experimental arms. A constant pro-
portion of 20% of subjects will be enrolled to the control
arm through the rest of phase II. Interim analysis will be exe-
cuted quarterly to adjust the randomization probabilities
based on the current interim analysis results. The proba-
bilities will be proportionally set to each experimental arm
based on arm with amax (more information and details is
described in Section 2.7.5).
2.7. Statistical modeling
This section describes the statistical modeling used in the adap-
tive design and the primary analysis. The modeling is Bayesian in
nature.
Two models – a pairwise independent response model and a
main effects response model – are utilized in this study. All of the
trial adaptations are driven by the pairwise independent model,
and we also identify the maximally effective experimental arm
with this model. The main effects model will be used to predict
phase III success, and this model assumes no interactions among
the different level combinations of HOBIT treatment factors and
will likely improve efficient prediction.
2.7.1. Pairwise independent response model for 6-month Glasgow
Outcome Scale - Extended response. The primary outcome is
6-month GOS-E response, and we label it for some subject i as
Yi,6. We model the 6-month primary outcomes as Bernoulli dis-
tributed. The model is [Yi,6]~Bernoulli(ai/, where ai D1,2,3,. . . ,10
is the arm for subject i.
We label the probability of the 6-month GOS-E response
for arm a as a. It is expected that GOS-E response for con-
trol arm and novel arms has the following prior distributions:
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Figure 1. Study design.
for the experimental arms where a D2,3,4,. . . ,10. According to the
previous clinical trials with the same endpoint, the control arm’s
prior on the response scale (1/ has a median of 0.40. If simu-
lated data are fitted to a beta distribution, the control arm’s prior
is equivalent to eight patients, that is, ˛0 C ˇ0 8, where ˛0
and ˇ0 are beta parameters. The novel arm’s prior median on the
response scale is higher than that of the control arm at 0.50 but
is much more vague because it is equivalent to only two patients
(similar to a uniform distribution, ˛0 C ˇ0 2).
2.7.2. Main effects model for 6-month Glasgow Outcome Scale -
Extended response used for phase III prediction. The main effects
model is [Yi,6]~Bernoulli(Pi/, for subject i. We construct a main
effects model for the GOS-E response rate that is a function of
pressure, NBH, and duration. The logit transformation of Pi is mod-
eled with a linear equation. By assuming no interaction among
the main factors, this model has a lower number of parame-
ters and is designed to increase confidence to predict phase III
success. However, if there is an interaction, there would be less
uncertainty in the predicted value, but there would be bias. This
scenario is explored later in trial simulations. The structure is
logit.Pi/ D Xi1C Xi2˛1.5ATA C Xi3˛2.0ATA
C Xi4˛2.5ATACXi5NBHCXi6ˇBID.
The Xs are 0 or 1 depending on the treatment factor combina-
tion assigned to subject i; µ represents the effect of control. The
˛’s represent the additional effect of pressure relative to control.
The  ’s and ˇ’s represent the additional effect of NBH and BID,
respectively. The main effects model relates to the control and
experimental arms in the following way:
(1) control 
(2) 2.0 ATA, without NBH, QD C ˛2.0ATA
(3) 2.5 ATA, without NBH, QD C ˛2.5ATA
(4) 1.5 ATA, with NBH, QD C ˛1.5ATACNBH
(5) 2.0 ATA, with NBH, QD C ˛2.0ATACNBH
(6) 2.5 ATA, with NBH, QD C ˛2.5ATACNBH
(7) 1.5 ATA, no NBH, BID C ˛1.5ATA C ˇBID
(8) 2.0 ATA, no NBH, BID C ˛2.0ATA C ˇBID
(9) 2.5 ATA, no NBH, BID C ˛2.5ATA C ˇBID
(10) 1.5 ATA ,with NBH, BID C ˛1.5ATACNBH C ˇBID
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The priors for GOS-E response for control arm and novel arm
have the following prior distributions: logit(/~N(-.41,.752/, the
control arm, and logit (all other parameters)~N(0,102/. The intu-
ition regarding the control arm’s prior is the same as the control’s
prior in the independent model. The prior for the additional
parameters’ is essentially flat (i.e., uniform on the real line).
2.7.3. Longitudinal model. In addition to the final 6-month end-
point, subjects will have a scheduled visit at 1 month. At any
interim analysis, there may be subjects in each of the following
categories: subjects who have completed all the visits with known
final endpoint; subjects who are still in the visit process without
final endpoint value; and subjects without data at all.
Let Yi,6be the final endpoint value for subject i and let Yi,1be the
1-month response. We construct a longitudinal model to allow
the unobserved 6-month endpoint to be imputed from the par-
tial data. The beta binomial longitudinal model updates two beta
distributions:
(1) The posterior probability that a subject who is a responder
at 1-month will be a responder at the 6 month endpoint:
Pr.Yi,6 D 1jYi,1 D 1/~Beta.˛1,ˇ1/,
where
˛1 D 20C jYi,6 D 1, Yi,1 D 1j, and
ˇ1 D 5C jYi,6D0, Yi,1 D 1j.
(2) The posterior probability that a subject who is a failure at
1-month will be a responder at the 6 month endpoint:
Pr.Yi,6 D 1jYi,1 D 0/~Beta.˛2,ˇ2/,
where
˛2 D 5C jYi,6 D 1, Yi,1 D 0j, and
ˇ2 D 20C jYi,6 D 0, Yi,1 D 0j.
In the aforementioned notation, jYi,6 D 1, Yi,1 D 1j indicates
a count of the number of subjects whose 6-month endpoint was
observed to be a response and whose intermediate outcome at
1-month was also a response. The other formulas with absolute
values have similar correspondence. We fit a set of models pool-
ing data across all arms. Note that our priors are fairly diffuse, and
each has a prior sample size equivalent to 25 subjects. This prior
was informed from previous TBI studies.
2.7.4. Bayesian quantities. The following Bayesian quantities used
in this adaptive design are calculated at each interim analysis.
From the joint posterior distribution, the posterior probability
that each arm, a D 2, 3, 4, . . . , 10 is the maximally effective arm,
Pmaxa , is calculated. The arm with the largest P
max
a is called the most
likely maximum effective novel treatment. The posterior mean and
variance for each GOS-E response rate is also calculated. We label
V.a/ as the posterior variance of the parameter a. For GOS-E
response rate, the posterior probability that experimental arm is
superior (larger response rate) to the control arm is calculated:
Pr.a > 1jdata/, where a D 2, 3, 4, . . . , 10. Each of these Bayesian
quantities is calculated using the data of all subjects who have
already completed the trials or are still in visit process for each
interim analysis.
2.7.5. Adaptive randomization details. The specification of the vec-
tor of probabilities for RAR is described in this section. The ran-
domization vector is created by selection based on the posterior
distribution of the GOS-E response for each arm.
The purpose of the adaptive randomization is to allocate sub-
jects to the arms most likely to be maximum effective. In addition,
the adaptive randomization could improve learning that is the
maximum effective arm is in comparison with the control arm.
A component, labeled as Va,is constructed for each arm. Set
V1 D1, assuring 1/5 probability for control arm throughout the
trial. The component for arms a D2,3,4,. . . ,10 is Va D 4Pmaxa for
a D2,3,4,. . . ,10. The randomization vector, q, is set as qa D Va/5
for a D1,2,3,4. . . ,10.
2.7.6. Phase III predictions. This adaptive design phase II clinical
trial provides valuable information to predict the success proba-
bility of a phase III clinical trial that aims to confirm the efficacy
and safety of optimal combination of HBO2 treatment factors for
severe TBI in comparison with the standard care. The primary
endpoint of the phase III trial will be the same as the one in phase
II, that is, sliding dichotomized GOS-E at 6 months, which will be
primarily analyzed by a chi-square test in the phase III study. The
sample size for phase III is 500 in the control and 500 in the novel
arms, totally n D1000, based on ˛ D0.05 and two-tailed.
Taking the maximally effective arm from phase II trial simula-
tions, we calculate the posterior predictive probability that there
is a >50% probability of hyperbaric treatment demonstrating
improvement in the rate of good neurological outcome versus
standard treatment in a subsequent phase III confirmatory trial.
This is calculated by the main effects model for the experimen-
tal arm that shows the maximum efficacy. To accomplish this, the
posterior predictive distribution for future responses of control
and novel arms, we label yP1and y
P
a , for arm a D2,3,. . . ,10, respec-


















a .1  Pa/
500yPa p .™jy/ d™ ,
where y is the observed data from the phase II trial and ™ is a vec-
tor of parameters from the main effects model. This distribution
is calculated using simulation. Suppose that a0 is the best HBO2
experimental arm identified in phase II, then the appropriate pre-
dictive chi-square test statistic is X2Pa0 which is calculated by y
P
1 and
yPa0 . To achieve a >50% success probability of phase III, two con-
ditions must be satisfied: (1) the main effects model indicates a
>94% probability that treatment of arm a’ is better than that in
control arm; (2) there is a >50% probability that X2Pa0 >3.841.
2.8. A comparison of pairwise independent and
main effects models
For the purposes of comparing the two models in a closed form
situation, the primary endpoint should be considered as a con-
tinuous response. Using a flat prior for regression parameters
and known variance, the posterior standard errors of the model
parameters representing the parameter estimation could be eas-
ily calculated. Consider the burn-in period, it can be easily shown,
for example, that the posterior standard error of the pairwise





5 D 0.6325 when ATA is 2.0.
The standard error within main effects model is 0.5578 ; thus,
the main effects standard error is 88% of the one of the pairwise40
0
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independent model, indicating the potential increase in effi-
ciency of the phase III use of the main effects model. More expli-
cated information will be provided in the illustration of Table V in
the results section. Obviously, this reduction comes with added
bias in case that an interaction does exist.
2.9. Software and computations
Computations were performed using three types of software:
Fixed and Adaptive Clinical Trial Simulator (FACTS) [16], R [17], and
Windows Bayesian inference Using Gibbs Sampling (WINBUGS)
[18]. General functions of these softwares are specified in Table I.
The pairwise comparisons model with the longitudinal modeling
and RAR was performed in FACTS. The main effects model was
performed using simulation in R2WINBUGS with custom coding.
First, FACTS is a software used to rapidly design, compare, and
simulate both fixed and adaptive trial studies. It is built on
compiled low-level languages, such as Fortran and CCC; thus,
it runs quite fast. Moreover, FACTS is flexible and easy to use
because it could be accessed through an interactive graphical
user interface. However, currently, FACTS does not have the capa-
bility to implement a main effects model. We decided to use
FACTS to simulate the pairwise independent model taking advan-
tage of its flexibility and speed, and then use the data output to
call a program that was written specifically for phase III predic-
tions in R2WINBUGS. The posterior simulated draws in FACTS were
1000 burn-in and then 2500 draws for inference. In WINBUGS, the
burn-in was 1000 and 1000 draws for inference.
2.9.1. Simulations. In FACTSTM, there is an option for defining
dichotomous longitudinal response profiles that allows us to
specify the overall transition probabilities between responder
(“1”) and non-responder (“0”). The transition probabilities method
Table I. Software we applied Software.
Software Function
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for generating longitudinal responses simulates the response
observed at each visit by using the probability that a subject
becomes or remains a “1” from one visit to the next – and all
subjects start with a response of 0.
We specify for each visit
 the probability of a subject whose response was a “0” at
the previous visit having a response of “1” at this visit
 the probability of a subject whose response was a “1” at
the previous visit having a response of “1” at this visit.
However, these probabilities give a particular probability that a
subject has a response of “1” at the final visit, so they need to be
modified for each arm in each dose response profile to give the
desired final probability of response. This is done by numerically
determining for each final response rate to simulate, a single value
Table II. Longitudinal data profile with
initial transition probabilities.
Visit Month Prob 1->1 Prob 0->1
1 1 – 0.5
2 6 0.8 0.2
Table III. Longitudinal data profile
after adjustment.
Visit Month Prob 1->1 Prob 0->1
1 1 – 0.664
2 6 0.888 0.330
that when added to all the specified transition probabilities in the
log-odds space yield the desired probability of final response.
With two visits (1-month and 6-months) and first visit probabil-
ity of 0->1 of 0.5 and then at the second visit probabilities of 0->1
of 0.2 and of 1->1 of 0.8, the probability of a final response is 0.5
(Table II).
If a response profile calls for the probability of a final response
to be simulated with a probability of 0.7, a fixed offset in log-odds
is found that when applied to all the transition probabilities
results in the desired final probability of a response. Replicat-
ing this by hand yields an offset of 0.68, which results in the
adjustment in Table III. All scenarios are adjusted in this fashion.
Glasgow Outcome Scale - Extended responses at 6-months of
all the treatment arms within different case scenarios are pre-
sented in Table IV. The first case is referred to as the null hypoth-
esis as each of the arms has identical GOS-E responses. All the
novel arms have no improvement in terms of GOS-E response in
comparison with the control arm. The remaining case scenarios
explore the different GOS-E responses for the experimental arms
including one case where harm is exhibited. The final case inves-
tigates the interactions of medium effect of pressure associated
with NBH and frequency, which aims to comprehend the possible
robustness of the main effects model.
3. RESULTS
In this section, we summarize the results of several simulation
cases as well as one additional null scenario case to control type
I error of the design. For each case, 1000 trials are simulated. We
present the results as a function of GOS-E response for each arm
at 6-month.
For all simulations in this section, we assume an accrual rate of
1.75 subjects per week. No drop outs are assumed.
Table IV. The adaptive clinical trial design evaluation via six case scenarios.
Case Scenario 1.0 Control 1.5 NBH 2.0, NBH 2.5, NBH 1.5, BID 2.0, BID 2.5, BID 1.5, NBH, BID 2.0 2.5
1. Null hypothesis 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
2. Small treatment effect 0.4 0.45 0.5 0.43 0.45 0.5 0.43 0.48 0.48 0.4
3. Medium treatment effect 0.4 0.5 0.55 0.48 0.5 0.5 0.48 0.55 0.5 0.43
4. Large treatment effect 0.4 0.57 0.7 0.52 0.57 0.7 0.52 0.65 0.63 0.45
5. Harmful treatment effect 0.4 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35
6. Medium Interaction 0.4 0.4 0.55 0.4 0.55 0.40 0.55 0.4 0.4 0.4
NBH, normobaric hyperoxia; BID, twice daily.
Table V. Simulated trial operating characteristics.
Power Futility Duration %Patient allocated to Probability (>50%)of
Case phase II prob. Size (n) (weeks) 2.0 ATA pressure arms phase III success*
1. Null hypothesis 0.20 0.34 176 118 33% 0.20
2. Small treatment effect 0.48 0.13 186 129 38% 0.51
3. Medium treatment effect 0.65 0.06 187 131 36% 0.71
4. Large treatment effect 0.96 0.01 174 125 45% 0.98
5. Harmful treatment effect 0.09 0.57 158 102 33% 0.08
6. Medium Interaction 0.63 0.09 185 106 33% 0.57
ATA, atmospheres absolute.
New calculation based on main effects model (S D 1000).40
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The study is considered a success if a target duration arm is
identified and phase III is recommended to be carried out. In the
simulations, if a trial enters a possible success stage, the trial is
stopped in the simulation.
We performed six sets of trial simulations based on the various
cases of response to calculate the trial operating characteristics,
that is, power, futility probability, sample size, duration, and sub-
ject allocation, which are presented in Table V. The first four cases
range from no effect (null) to large treatment effect. All these
four cases have no interaction between factors. We could clearly
see an increase in power (starting with a 20% type I error rate)
but a decrease in futility rates as the effect increases. Because
the null trial has a higher chance to stop for futility, the balance
switches in a higher probability to stop for success as the benefit
moves to large. Both the sample size and duration increase from
null hypothesis to medium treatment effect and then go down
in large treatment effect. The percentage of patients placed in
the best pressure (2.0 ATA) arms generally increases as treatment
effect increases. The probability of phase III success is uniformly
larger than the power for phase II because of the added efficiency
of the main effects model. The fifth case has explored charac-
Figure 2. Allocation of subjects across arms for one simulated medium effect
case for RAR with longitudinal (RARCL) versus the fixed designs. Probability arm
a D2,3,4„. . . ,10 is better than control.
teristics, including the futility with a high rate, of the harmful
treatment effect. Additionally, the medium interaction case has
similar operating characteristics to the medium treatment effect
case without interaction except that its probability (>50%) of
phase III success prediction is lower than the phase II power. Of
note, the estimated sample size of fixed trials that is 325 and would
give similar power is substantially larger.
Figure 2 illustrates the patient allocation comparison of RARCL
and fixed one based on a single simulation’s MCMC results. More
subjects are placed on control for the RARCL. There are also more
subjects placed on the better experimental arms, and the top two
are the third and sixth arms. Further, the incremental improve-
ment in the efficiency is shown by the decrease in the posterior
standard deviation from pairwise independent model to a main
effects model, illustrating the increase in prediction ability by the
latter model. The standard deviation (Figure 3) for the main effects
model was on average 79% of the pairwise independent model,
which is very similar to the approximate approach discussed in
Section 2.9.
Figure 3. Posterior mean and posterior standard deviation of Glasgow Outcome
Scale - Extended from subjects across treatment arms for one simulated medium
effect case for pairwise independent and main effects models.
Table VI. Simulated trial operating characteristics for different designs
using large effect.
Design Power phase II Futility prob. Size (n) Duration (weeks)
1. Fixed 0.88 0.00 200 140
2. RAR 0.94 0.02 176 126
3. RARCL 0.96 0.01 174 125
RAR, response adaptive randomization; RARCL, RAR with longitudinal.
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3.1. RAR with longitudinal versus response adaptive
randomization versus fixed
We present the adaptive design in terms of RAR (no longitudinal)
and RARCL (adding longitudinal modeling) over the fixed design
(no early stopping, no longitudinal modeling, and no RAR) to illus-
trate the incremental treatment effect (Table VI). Note that the
two alternative adaptive designs were recalibrated (i.e., chang-
ing what the decision rule is for success and/or futility) so that all
designs have the same type I error of 20% and futility rate is 34%
in the case of “null hypothesis” (Table V). This allows for a fair com-
parison across designs. First, both RAR and RARCL have a 6% and
9% power increases over the fixed design, respectively. The rela-
tive reduction of sample size in the RAR and RARCL is 24 and 26,
and the relative reduction of trial duration in the adaptive designs
of RAR and RARCL is14 and 15 weeks, respectively.
4. DISCUSSION
This manuscript presents a phase II clinical trial design that
applies both pairwise independent and main effects models to
explore whether one treatment for severe TBI is good enough to
carry out a further phase III trial as well as to predict the prob-
ability of future success. This approach can identify the optimal
treatment factor combinations in terms of pressure, duration, and
addition of NBH to HBO2 for severe TBI. The pairwise independent
model “drives” the RARCL modeling, and main effects model uses
the data in such a trial for the phase III study prediction.
The main effects model is applied to the specific HBO2 treat-
ment provided by the trial’s goal of choosing an arm and pre-
dicting this arm’s phase III success probability. Moreover, the
utilization of this approach will be identical in any clinical trial
in which investigators are interested in adding efficiency of the
prediction through the suppression of the interaction terms in
the main effects. Also, this type of modeling is not limited to a
binary endpoint, for example, external reviewers of our full clin-
ical trial research plan wanted biological ties to the trial rather
than solely based on clinical endpoint provided by the GOS-E.
Therefore as a secondary outcome, it was proposed to measure
intracranial pressure and model this as a continuous biological
response. A main effects model was also used here, but rather
than a binary response, a normal distribution response was used.
We used the expected sample sizes for power calculations for the
secondary endpoints.
The investigation in this manuscript is distinct from the dose
finding models where investigators might be interested in sim-
ilar optimization but of a single continuous factor, and those
types of trials regarding dose finding have been investigated in
RARCL modeling and have provided nice innovations to the clin-
ical trials toolbox. However, investigators may commonly face the
issue of multiple factor selection; the approach explored in this
manuscript would be a good reference for them to identify the
novel treatment.
The model that we propose assumes that there is no inter-
action between the multiple factors in the step that predicts
phase III success. We use this assumption because the sample
size of the phase II trial is relatively small and that the GOS-E
endpoint is a noisy binary variable (e.g., relative to a continuous
endpoint). Therefore, it would be benefit to try to find efficiencies
through the statistical model. This main effects model “collapses”
these factors together so that each level of pressure is providing
information in three cells of the model. Of note, we do not inves-
tigate each experimental arm of treatment factors that the 3x2x2
factorial model could provide, which with control arm would be
13 arms. Although it would be more efficient to keep all of the
factor combinations in the design from a statistical viewpoint, the
trade-off of clinical trials between risk–benefit while providing a
wide enough net to grab potentially important novel treatments
must be balanced. Thus, three factor combinations with too high
oxygen dose were eliminated based on medical considerations.
A second note is that while the phase III calculations suppress
the interaction, the phase II portion uses the pairwise indepen-
dent means model that actually allows for interactions of the
multiple factors.
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